Schizophrenia Pipeline Insight: Analysis of 90+ key pipeline therapies, 90+ key pharma competitors, unmet needs, and opportunities

February 24 15:11 2021
Schizophrenia Pipeline Insight: Analysis of 90+ key pipeline therapies, 90+ key pharma competitors, unmet needs, and opportunities

Schizophrenia Pipeline Insight

Schizophrenia Pipeline Insight” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Schizophrenia market. A detailed picture of the Schizophrenia pipeline landscape is provided, which includes the disease overview and Schizophrenia treatment guidelines.

 

Some of the key highlights from the Schizophrenia Pipeline report:

  • 90+ key pharma players are proactively working to propel the Schizophrenia market landscape by 2026-27.
  • Over 90+ Schizophrenia pipeline therapies are under different stages of development and their expected approval in the Schizophrenia market shall uplift the market revenue significantly. 
  • Out of emerging therapies, SEP-363856 is in Phase III of clinical development, whereas, AVP-786 is in Phase II/III stage of trials. Similarly, MK-8189 is undergoing Phase II developmental phase for Schizophrenia. 
  • Schizophrenia pipeline therapies in the early stages of development include CAD-9303, and CVL 231 in Phase I of clinical trials.
  • In December 2020, FDA assigns PDUFA action date of (01/06/2021) for ALKS 3831 for Schizophrenia and Bipolar disorders.
  • In June 2020, Neurocrine Biosciences and Takeda entered into a strategic collaboration agreement to develop and commercialize compounds in Takeda’s early-to-mid-stage psychiatry pipeline. Takeda granted an exclusive license to Neurocrine Biosciences for seven pipeline programs, including three clinical-stage assets for schizophrenia, treatment-resistant depression, and anhedonia.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/schizophrenia-pipeline-insight

 

Schizophrenia Pipeline Analysis: Drug Profile 

  • SEP-363856: Sunovion Pharmaceuticals

SEP-363856 is a TAAR1 agonist with 5-HT1A agonist activity. The therapy is under trial for the treatment of schizophrenia and other psychiatric conditions. Sunovion is running a global Phase III development program for schizophrenia (DIAMOND) with additional indications under consideration. 

NCT04109950: Study SEP361-301 or Study SEP361-302,  “an open-label extension study to assess the safety and tolerability of SEP-363856 in subjects with Schizophrenia”, is currently in the recruiting stage with an estimated enrollment of 555 participants and expected to be completed in November 2022.

NCT04072354: Sunovion initiated a phase III trial titled “A randomized, double-blind, parallel-group, placebo-controlled, fixed-dose, multicenter study to evaluate the efficacy and safety of SEP-363856 in Acutely Psychotic Subjects with Schizophrenia”, which is expected to be completed in September 2021.

  • Doria (Risperidone extended-release): Rovi Pharmaceuticals Laboratories

Doria is a monthly intramuscular injection that does not require loading doses or concurrent oral risperidone. It is a new long-acting injectable (LAI) intramuscular formulation of risperidone, for monthly administration without oral supplementation. As researchers suggest that the intramuscular route of administration is more effective compared to oral, hence Doria is expected to generate the highest market share compared to other therapies. It is in the preregistration stage for Schizophrenia in the USA.

  • Roluperidone (MIN-101): Minerva Neurosciences

Roluperidone is meant to block a specific subtype of serotonin receptor called 5-HT2A. When 5-HT2A is blocked, certain symptoms of schizophrenia, such as hallucinations, delusions, agitation, and thought and movement disorders, as well as the side effects associated with antipsychotic treatments, can be minimized. Additionally, blocking 5-HT2A promotes slow-wave sleep, a sleep stage often disrupted in patients with schizophrenia. It is currently in phase 3 of clinical trials and in December 2020 Minerva Neurosciences announces its intention to request a pre-NDA meeting with the US FDA for planned NDA submission of Roluperidone for Schizophrenia.

 

Dive deeper to know more @ Schizophrenia therapeutics and drugs pipeline

 

Key Pipeline Therapies along with Schizophrenia Companies

  • TV-44749: Teva Pharmaceutical 
  • AVP-786: Avanir Pharmaceuticals
  • CAD-9303: Cadent Therapeutics
  • CVL 231: Cerevel Therapeutics
  • SEP-363856: Sunovion Pharmaceuticals
  • Doria: Rovi Pharmaceuticals Laboratories
  • Roluperidone: Minerva Neurosciences
  • Lu AF11167: H. Lundbeck A/S
  • KarXT: Karuna Pharmaceuticals
  • MK-8189: Merck
  • NaBen: SyneuRx International
  • TAK-831: Takeda
  • RL 007: Recognify Life Sciences
  • Dexmedetomidine (BXCL501): BioXcel Therapeutics
  • RO-6889450: Roche
  • Evenamide: Newron Pharmaceuticals
  • BI 409306: Boehringer Ingelheim
  • PF 6412562: Pfizer
  • ALKS 3831: Alkermes plc 
  • Pimavanserin:  ACADIA Pharmaceuticals

 

Got queries? Reach out for more information @ Schizophrenia Drug Pipeline Assessment 

 

Scope of the Report

  • Coverage: Global
  • Key Market Players: Teva Pharmaceutical, Avanir Pharmaceuticals, Cadent Therapeutics, Cerevel Therapeutics, Sunovion Pharmaceuticals, Rovi Pharmaceuticals Laboratories, Acadia Pharmaceuticals, Pfizer, Merck Sharp & Dohme, Karuna Pharmaceuticals, Takeda, GW Pharmaceuticals, Alkermes, Lundbeck A/S, Roche, Boehringer Ingelheim, Celon Pharma, SyneuRx International, Avineuro Pharmaceuticals, Recognify Life Sciences, among others.
  • Key Pipeline Therapies: TV-48438, AVP-786, CAD-9303, CVL 231, Lu AF11167, KarXT, PF 6412562,MK-8189, GWP42003, RO6889450, CPL500036, NaBen, AVN 211, RL 007, among others.
  • Novel Therapies: Doria, Roluperidone, Dexmedetomidine, SEP363856, Pimavanserin, ALKS 3831, BI 409306, KarXT, and Evenamide.

 

Table of contents

1. Report Introduction

2. Schizophrenia 

3. Schizophrenia Current Treatment Patterns

3.1. Schizophrenia Treatment Guidelines

4. Schizophrenia – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Schizophrenia Late Stage Products (Phase-III)

7. Schizophrenia Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Schizophrenia Discontinued Products

13. Schizophrenia Product Profiles

14. Schizophrenia Key Companies

15. Schizophrenia Key Products

16. Dormant and Discontinued Products

17. Schizophrenia Unmet Needs

18. Schizophrenia Future Perspectives

19. Schizophrenia Analyst Review  

20. Appendix

21. Report Methodology

Get in touch with our Business Executive @ BK virus (BKV) Infection Pipeline Trends and Futuristic Outlook to learn more about the domain.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/schizophrenia-pipeline-insight


Warning: count(): Parameter must be an array or an object that implements Countable in /home/haridwartoday/gorakhpurreporter.in/wp-content/themes/gadgetine-theme/includes/single/post-tags-categories.php on line 7